FDG-PET vs. chemical shift MR imaging in differentiating intertrabecular metastasis from hematopoietic bone marrow hyperplasia

Jpn J Radiol. 2021 Nov;39(11):1077-1085. doi: 10.1007/s11604-021-01149-x. Epub 2021 Jun 8.

Abstract

Purpose: To evaluate the utility of SUVmax on FDG-PET and chemical shift imaging (CSI) on MRI in the differentiation of intertrabecular metastasis (ITM) from hematopoietic bone marrow hyperplasia (HBMH).

Patients and methods: We retrospectively evaluated 54 indeterminate focal bone marrow lesions in 44 patients detected on FDG-PET. The lesions were assigned to the metastasis group (M group, 29 lesions of 24 patients) and the non-metastasis group (non-M group, 25 lesions of 20 patients) based on the follow-up or the histopathological studies. The lesions were assessed with the maximum standardized uptake value (SUVmax) on FDG-PET CT images and signal change ratio (SCR) on CSI.

Results: The median SUVmax were 5.62 and 2.91; the median SCR were - 0.08 and - 34.8 in M and non-M groups respectively, with significant difference (p < 0.001). With ROC curve analysis, the optimal cutoff value of SUVmax was 4.48 with a sensitivity of 72.4%, a specificity of 100%, and AUC of 0.905. The cutoff value of SCR was - 6.15 with a sensitivity of 82.8%, a specificity of 80%, and AUC of 0.818.

Conclusion: FDG-PET and CSI on MRI are useful in distinguishing ITM from HBMH. Though their sensitivities are similar, the specificity of FDG-PET was higher than that of MRI.

Keywords: Chemical shift imaging; FDG-PET CT; Hematopoietic bone marrow hyperplasia; Intertrabecular metastasis; MRI.

MeSH terms

  • Bone Marrow* / diagnostic imaging
  • Fluorodeoxyglucose F18*
  • Humans
  • Hyperplasia
  • Magnetic Resonance Imaging
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Retrospective Studies

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18